Pharmacokinetic modelling—A prelude to therapeutic drug monitoring for all cancer patients?
- 31 October 1995
- journal article
- editorial
- Published by Elsevier in European Journal Of Cancer
- Vol. 31 (11) , 1733-1735
- https://doi.org/10.1016/0959-8049(95)00508-g
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Prediction of Carboplatin Clearance From Standard Morphological and Biological Patient CharacteristicsJNCI Journal of the National Cancer Institute, 1995
- American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines.Journal of Clinical Oncology, 1994
- Epirubicin in hepatocellular carcinoma: pharmacokinetics and clinical activityCancer Chemotherapy and Pharmacology, 1994
- Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer.Journal of Clinical Oncology, 1992
- Effectiveness of carboplatin, etoposide, and bleomycin combination chemotherapy in good-prognosis metastatic testicular nonseminomatous germ cell tumors.Journal of Clinical Oncology, 1991
- Etoposide kinetics in patients with obstructive jaundice.Journal of Clinical Oncology, 1990
- Carboplatin dosage: prospective evaluation of a simple formula based on renal function.Journal of Clinical Oncology, 1989
- Clinical Pharmacodynamics of High-Dose Methotrexate in Acute Lymphocytic LeukemiaNew England Journal of Medicine, 1986
- METHOTREXATE SYSTEMIC CLEARANCE INFLUENCES PROBABILITY OF RELAPSE IN CHILDREN WITH STANDARD-RISK ACUTE LYMPHOCYTIC LEUKAEMIAThe Lancet, 1984
- Use of Plasma Pharmacokinetics to Predict and Prevent Methotrexate ToxicityNew England Journal of Medicine, 1977